Seven Mile Advisory Buys New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Seven Mile Advisory purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,668 shares of the biopharmaceutical company's stock, valued at approximately $246,000.

A number of other hedge funds also recently modified their holdings of GILD. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 1.9 %

GILD stock traded down $2.12 on Friday, reaching $110.27. 5,371,465 shares of the company traded hands, compared to its average volume of 7,319,789. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a fifty day simple moving average of $107.02 and a 200-day simple moving average of $95.63. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a market cap of $137.30 billion, a P/E ratio of 298.02, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a $0.79 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GILD shares. Bank of America lifted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Morgan Stanley upped their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. Finally, The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.